Actively Recruiting
Early Biomarkers in Premanifest Huntington's Disease Gene Carriers: a Pilot Study
Led by University Hospital, Grenoble · Updated on 2025-01-20
20
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating early signs of Huntington's disease in people who carry the gene but do not yet show symptoms. This study aims to find new biomarkers by comparing genetic carriers with healthy individuals using functional brain MRI and gait analysis with virtual reality. The goal is to detect early brain and movement changes before symptoms appear, helping to understand disease progression and improve future treatments. Participants will undergo several assessments including a visual stimulation during functional MRI to study brain responses, especially focusing on the superior colliculus and other visual areas. Gait will be evaluated using advanced 3D virtual reality equipment during different walking scenarios. Emotional and cognitive functions will be assessed through eye-tracking and additional MRI sessions involving viewing emotional images and performing related tasks. The study involves multiple visits where participants receive neurological, ophthalmological, and neuropsychological evaluations. Brain imaging, eye movement tracking, and gait measurements will be performed at set intervals. Researchers will analyze brain activity, gait parameters, and emotional behavior to detect early abnormalities. The entire study from enrollment to the end of investigations will last about two months, with careful monitoring and data correlation to explore potential early markers of Huntington's disease.
CONDITIONS
Brief Title
Early Biomarkers in Premanifest Huntington's Disease Gene Carriers: a Pilot Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- For premanifest genetic carriers: confirmed Huntington's disease diagnosis by genetic testing with 36 or more CAG repeats in the HTT gene
- Unified Huntington Disease Rating Scale Total Motor Score of 5 or less
- Age between 18 and 70 years
- For healthy controls: normal neurological exam
- Age between 18 and 70 years
You will not qualify if you...
- Presence of major active eye or psychiatric diseases
- Cognitive impairment with Montreal Cognitive Assessment score less than 25 out of 30
- Gait problems caused by non-neurological conditions
- Contraindications to brain MRI
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 2 months
Participants undergo a series of assessments including neurological examination, ophthalmologic visit, neuropsychological assessment, brain functional MRI with visual stimulation, gait assessment using 3D virtual reality equipment, and cognitive/emotional testing with eye-tracking and fMRI to investigate early biomarkers of Huntington's disease.
6 visits (in-person)
Trial Site Locations
Total: 1 location
1
Grenoble University Hospital
Grenoble, France, 38043
Actively Recruiting
Research Team
S
Sara Meoni, MD, PhD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here